Pharma Veteran Tim Rudolphi Takes the Helm at metaMe Health

Timothy R2.jpg

Chicago-based metaMe Health has announced the appointment of Tim Rudolphi as its Chief Executive Officer (CEO).   metaMe’s mission is to create FDA-cleared digital therapeutics for the treatment of gastrointestinal conditions.  The company’s lead product is Regulora™, a fully digital behavioral intervention for the treatment of Irritable Bowel Syndrome (IBS).

Rudolphi has 30 years of pharmaceutical and healthcare experience with a diverse background in sales, global and US marketing, commercial operations, strategic planning and business development. Most recently Tim was Senior Vice President and advisor to the Chairman of Cincinnati, Ohio-based Aprecia Pharmaceuticals, a privately held specialty pharmaceutical company focused on 3-D printing technology.  Prior to Aprecia, Tim helped build Takeda Pharmaceuticals, starting with the company in 1999.  He took on increasing roles of responsibility including leading the US Sales & Managed Markets, Marketing, and BD teams. Tim began his career in pharmaceuticals spending 12 years with Parke-Davis Pharmaceuticals.

 “Throughout his 30+ year career in the pharmaceutical industry, Tim has extensive experience in marketing, business development, strategic planning, sales management, product launches, and alliance partnering,” said Danny Bernstein, Founder and Chief Product Officer of metaMe Health.  “As we move closer to gaining FDA-clearance on Regulora, Tim’s experience in developing and executing highly successful commercialization strategies and plans will be vital to metaMe’s ultimate success.”

metaMe Health was created to help the more than 30 million Americans, or about 10% of the US population,   obtain much-needed relief from IBS.  Regulora is the first digital implementation of a behaviorally-focused treatment that addresses the cognitive, behavioral and affective drivers of IBS.  Regulora is based on an IP-protected fully standardized intervention.

“metaMe is at the forefront of bringing prescription digital therapeutics to reality and I’m honored and excited by the opportunity to lead this organization in its next phase of growth,” said Rudolphi.

Shawn Thurlow